It has been reported that approximately half of Japanese lung adenocarcinoma patients have EGFR mutations, and approximately 30% of patients have no identified driver genes, such as KRAS, ALK fusion, or RET fusion genes (pan-negative)40. This evidence concerns the gene ALK and lung adenocarcinoma.